- Fellowship - UT Southwestern Medical Center (1989-1991), Surgery Urological
- Residency - Army Hospital (1982-1986), Surgery Urological
- Internship - Army Hospital (1981-1982), Surgery Urological
- Medical School - Justus-Liebig-University Giessen
Claus Roehrborn, M.D.
- S.T. Harris Family Chair in Medical Science, in Honor of John D. McConnell, M.D.
- E.E. Fogelson and Greer Garson Fogelson Distinguished Chair in Urology
- Genitourinary Cancer
- Male Urology
A world-renowned urologist and expert on cancerous prostate diseases, Claus Roehrborn, M.D., has been practicing at UT Southwestern for more than 20 years and has been Chair of the Department of Urology since 2002. Under his leadership, the Department has consistently been named among the nation’s best by U.S. News & World Report.
Dr. Roehrborn’s practice focuses on the treatment of prostate cancer and benign prostatic hyperplasia (BPH). Over the past several years, he has performed more than 1,200 robotic prostatectomies for prostate cancer and more than 800 laser prostatectomies for BPH, making him one of the country’s most experienced surgeons in the use of robotic procedures for urologic conditions. In addition, he is involved in virtually all aspects of BPH research as well as translational and clinical research in prostatitis and prostate cancer.
Born and raised in the former West Germany, Dr. Roehrborn earned his medical degree from Justus Liebig University in Giessen and began his residency in surgery and urology at the German Army Hospital there. He was initially drawn to urology during medical school because of the comprehensive nature of the specialty that allows physicians to see patients, do their own medical tests, diagnose their conditions, operate on them if necessary, and then do follow-up care.
In 1984 Dr. Roehrborn moved to Dallas and continued his studies at UT Southwestern where he received advanced training in urologic endocrinology. He became a faculty member of UT Southwestern in 1992.
In 2018, Dr. Roehrborn was included in D Magazine's Best Doctors list and was named a Super Doctor by Texas Monthly. In 2010, he was the recipient of the Patricia and William L. Watson Jr., M.D., Award for Excellence in Clinical Medicine, which recognizes a UT Southwestern clinician whose work exemplifies a commitment to outstanding patient care and advancement of innovative medical therapy. The recipient of the award is chosen by a panel of colleagues and peers.
Meet Dr. Roehrborn
Urologist Specializing in Prostate Cancer
Claus Roehrborn, M.D., a urologist with special expertise in prostate cancer, has devoted his career to researching and treating prostate diseases. The greatest reward? “When a patient sends his son, brother, uncle, or father to see me — even from far-away places,” he says. “That tells me the patient thinks there’s no one else he would rather have his family member see.”
“I visit with patients. I sit down with them and take their history. I do my own diagnostic evaluation, prostate biopsies, and surgeries. So patients are cared for by me in a very personal manner.”
Among many awards, Dr. Roehrborn is consistently recognized as a Best Doctor by D Magazine and a Super Doctor by Texas Monthly. The Department of Urology at UT Southwestern is nationally ranked in U.S. News & World Report's America's Best Hospitals 2013.
Lots of people put their trust in Dr. Roehrborn. He’s performed more than 1,200 urologic surgeries using advanced robotic techniques that offer patients the fastest possible return of continence and sexual function. That level of expertise is unmatched in North Texas.
“Robotic surgery has added immensely to the quality of outcomes for my patients,” Dr. Roehrborn says. “It combines the best of minimally invasive laparoscopic surgery with 3-D imaging and magnification capabilities that in my experience are unbeatable. It gives patients with prostate problems and diseases a very quick and very early return of both continence and potency.”
An expert in prostate cancer, Dr. Roehrborn maintains a blog where he discusses issues in urology and prostate diseases, including controversies over prostate-specific antigen (PSA) testing. He’s also a proponent of active surveillance programs for prostate cancer, rather than immediately commencing treatment whenever it’s found. “Active surveillance is often not chosen by community urologists,” he says. “But oftentimes patients who have been diagnosed with prostate cancer by way of PSA testing have a low stage of the disease and may actually benefit more from surveillance.”
- South Central Section of the American Urological Association (SCS AUA)
- Societe Internationale Urologique (SIU)
- European Association of Urology (EAU)
- American Urological Association (AUA)
- American Medical Association
- Invited Visiting Professor and Lecturer, Multiple Urological Organizations in over 30 countries
- Special Recognition AUA Guidelines 1997, For extraordinary contributions to the AUA Guidelines Effort
- SIU Guest Lecture 2002, Invited Guest Lecturer at the German Urological Meeting to give the SIU Guest Lecture
- Texas Super Doctor 2004 - 2013 2004, Selected by peers in the state of Texas
- Dallas Best Doctor 2004 - 2013 2004, Selected by peers in 2004 - 2013
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
Andrew J. Stephenson, Shahrokh F. Shariat, Michael J. Zelefsky, Michael W. Kattan, E. Brian Butler, Bin S. Teh, Eric A. Klein, Patrick A. Kupelian, Claus G. Roehrborn, David A. Pistenmaa, Heather D. Pacholke, Stanley L. Liauw, Matthew S. Katz, Steven Leibel, Peter T. Scardino and Kevin M. Slawin American Medical Association (Reprinted JAMA) 2004 1325-1332
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence
Karam JA, Lotan Y, Roehborn CG, Ashfaq R, Karakiewicz PI, Shariat SF Prostate 2007 67 614-622
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer.
Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N Cell 2013 Aug 154 5 1074-84
The long-term effect of doxazosin finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
John D. McConnell, Claus G. Roehrborn, Oliver M. Bautista, Gerald L. Andriole, Jr., et al New England Journal of Medicine 2003 349 2387-2389
Tolterodine and tamsulosin for treatment of men with lower urinary tract symtpoms and overactive bladder, a randomized controlled trial
Kaplan SA, Roehrborn CG, Rovner EDs, Carlsson M, Bavendam T, Guan Z JAMA 2006 296(19) 2319-2328
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response
Leonard S. Marks, Claus G. Roehrborn, Eric Wolford and Timothy Wilson Journal of Urology 2007 177(4) 1408-1413
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling
Serfling R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG, Rittmaster R J Urol 2007 177 2352-2356
Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millenium
Chun FK, Briganti A, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI European Urology 2007
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical syctectomy
Jose A. Karam, Yair Lotan, Pierre I. Karakiewicz, Raheela Ashfaq, Arthur I. Sagalowsky, Claus G. Roehrborn, Shahrokh F. Shariat The Lancet 2007 8 128-136
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A J Clin Oncol 2007 25 2035-2041
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
D’Amico AV, Roehrborn CG Lancet Oncol 2007 8 21-25
Multi-Center Randomized Controlled Blinded Study of the Prostatic Urethral Lift for the Treatment of LUTS Associated with Prostate Enlargement Due to BPH: The L.I.F.T. Study.
Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Brown BT, McVary KT, Te AE, Gholami SS, Rashid P, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield SK, Borges FD, Rukstalis DB The Journal of urology 2013 Jun
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L BJU international 2013 May
- Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
- Urological Ultrasound
- Tumor markers
- Prostate cancer
- Outcomes research
- da Vinci Robotic Prostatectomy
- Benign prostatic hyperplasia
- Genitourinary Cancer
- Male Urology
- Prostate Cancer